Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Gelibter
Alain J
AJ
Lonardi
Sara
S
Di Segni
Susanna
S
Fontana
Andrea
A
Loupakis
Fotios
F
Cognetti
Francesco
F
Labianca
Roberto
R
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D000069287:Capecitabine; D002986:Clinical Trials as Topic / Q000379:methods*; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil / Q000031:analogs & derivatives; D041981:Gastrointestinal Tract / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D012107:Research Design
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003841:Deoxycytidine; D000069287:Capecitabine; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil